Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 3/20 | 0.44 |
| ▸ | MMP12 | P39900 | 2/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.43 |
| ▸ | PTGES | O14684 | 3/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
| ▸ | STAT3 | P40763 | 2/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.39 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2246642 | 0.88 | MMP12 (0.41) | MMP12MMP13FFAR1PTGESALOX5 | |
| SCHEMBL4369489 | 0.87 | PTGES (0.45) | MMP12MMP13FFAR1PTGESALOX5 | |
| SCHEMBL5653131 | 0.85 | CYP1A2 (0.46) | FFAR1PTGESALOX5MEN1KMT2A | |
| SCHEMBL5651081 | 0.84 | PTGES (0.53) | MMP12PTGESALOX5 | |
| SCHEMBL4359337 | 0.84 | MMP12 (0.39) | MMP12MMP13FFAR1PTGESALOX5 | |
| SCHEMBL4623713 | 0.84 | TRPM8 (0.46) | FFAR1PTGESALOX5MEN1KMT2A | |
| SCHEMBL4365889 | 0.83 | PTGES (0.45) | MMP12PTGESALOX5LPAR1 | |
| SCHEMBL27826145 | 0.83 | TRPM8 (0.46) | MEN1KMT2A | |
| SCHEMBL5650382 | 0.82 | MEN1 (0.46) | MEN1KMT2ALPAR1LPAR5 | |
| SCHEMBL2246723 | 0.81 | MMP12 (0.44) | MMP12MMP13PTGESALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | ADAMTS5, ADAMTS1, ADAMTS7 | SRD5A2 3124/4885MMP12 54/4885MMP13 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.